Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06234995 · ClinicalTrials.gov registry record · Phase 4
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
A Phase 4 study of Parkinson Disease, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06234995: Recruiting Phase 4 study of Parkinson Disease, sponsored by Emory University.
NCT06234995 is a Phase 4 study of Parkinson Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 80 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06234995, a Phase 4 study of Parkinson Disease, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
Primary Outcome
The GNG task is a tool for measuring impulsiveness by asking participants to respond to a cue signal for pressing a button. There are Go trials, where the button should be pressed, and No-Go trials, where the button should not be pressed. A total of 240 trials will be administered (5 blocks of 30) after an initial practice block (12 trials). An additional 120 Go only trials will be administered prior to the Go/No-Go blocks and serve as a control without inhibitory demands. Participants with PD a
Conditions Studied
Interventions
- DRUG Levodopa
- DEVICE Clinical DBS Setting
- DEVICE Sham DBS
- DEVICE DBS Setting Maximizing Prefrontal Activation
- DEVICE DBS Setting Minimizing Prefrontal Activation
Study Locations (2)
Georgia
- Emory University Hospital - Atlanta
- Emory Brain Health Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
What NCT06234995 shows while recruiting
NCT06234995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 5 interventions - of which Levodopa is the first listed.
NCT06234995 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06234995 about?
NCT06234995 is a clinical study titled "Cortical Electrophysiology of Response Inhibition in Parkinson's Disease". Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involv...
What is the current status of trial NCT06234995?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2021-08-09. Estimated completion is 2026-07-31.
What conditions does trial NCT06234995 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06234995?
The interventions under investigation include: Levodopa (DRUG), Clinical DBS Setting (DEVICE), Sham DBS (DEVICE), DBS Setting Maximizing Prefrontal Activation (DEVICE), DBS Setting Minimizing Prefrontal Activation (DEVICE).
Who is sponsoring clinical trial NCT06234995?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06234995 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06234995's enrollment target sits among peer trials
80 105th of 297 higher than 189 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
RECRUITING · Phase 4
-
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
RECRUITING · Phase 4
-
Personalized Real-Time DBS and PD Mechanisms
RECRUITING · Phase 4
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI